News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Glenmark will begin distribution in November 2025
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated
